Valsartan, Sacubitril — Drug Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

6 Recruiting

7 Completed trials

12 Sponsors

14 Countries

Phase III

Phase II

Phase III/IV

Phase IV

Other

Phase III: 4 Phase II: 2 Phase III/IV: 2 Phase IV: 3 Other: 2

Oversight events:

9 temporary halts 1 urgent safety measure across 1 trial

View oversight register →

Sponsors using this IMP

Laboratorios Normon S.A. 2 Akershus University Hospital 1 Andrea Di Marco 1 Assistance Publique Hopitaux De Paris 1 Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda 1 Krakowski Szpital Specjalistyczny Im. Sw. Jana Pawla II 1 Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy 1 Novartis Pharma AG 1 Slaskie Centrum Chorob Serca W Zabrzu 1 University Of Oxford 1 Uniwersytecki Szpital Kliniczny W Poznaniu 1 Ziekenhuis Oost Limburg 1

All trials

13 total

Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testi… Recruiting

2025-521780-12-00 Phase III/IV 1 country Andrea Di Marco
Effect of pharmacological treatment with angiotensin receptor/neprilysin inhibitors on transthyretin cardiac amyloidosis and heart failure w… Recruiting

2024-515661-34-00 Phase IV 1 country Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De H…
Beta-blOckers discoNtinuation in patients presenting heart FaIlure with REcovered left ventricular ejection fraction Recruiting

2023-508798-94-00 Phase III 1 country Assistance Publique Hopitaux De Paris
Sacubitril/Valsartan in prevention of heart damage during breast cancer treatment Recruiting

2024-517804-12-00 Phase III 1 country Slaskie Centrum Chorob Serca W Zabrzu
Sacubitril/valsartan in the prevention of disease progression in patients with an ancient arrhythmogenic service - ARNI-ARVC multicentre ran… Recruiting

2024-517412-29-00 Phase III 1 country Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut …
The effect of sacubitril/valsartan versus ramipril on left ventricular function and remodeling in patients with ischemic heart failure with … Recruiting

2024-518239-12-00 Phase III 1 country Krakowski Szpital Specjalistyczny Im. Sw. Jana Pawla II
Prevention of cardiac Dysfunction during Adjuvant breast cancer therapy: A Randomized, Placebo-controlled, Multicenter Trial (PRADA-II) Ended

2024-515323-11-00 Phase II 1 country Akershus University Hospital
A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended

2023-504678-39-00 Phase II 11 countries Novartis Pharma AG
PRAISE-MR trial Ended

2023-506634-70-00 Phase IV 1 country Ziekenhuis Oost Limburg
Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart… Ended

2022-502409-14-00 Phase III/IV 1 country University Of Porto
Bioequivalence clinical trial of two formulations of sacubitril/valsartan Ended

2023-505237-27-00 1 country Laboratorios Normon S.A.
Bioequivalence clinical trial of two formulations of sacubitril/valsartan Ended

2022-503083-32-00 1 country Laboratorios Normon S.A.
Pulmonary REsistance modification under treatment with Sacubitil/valsartaN in paTients with HeartFailure with reduced ejection fraction Ended

2024-517975-19-00 Phase IV 1 country Uniwersytecki Szpital Kliniczny W Poznaniu

Showing 1–13 of 13 trials

← All drugs A–Z